#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Juvenile chronic myelomonocytic leukaemia Precursor T-lymphoblastic lymphoma/leukaemia recurrent Leukaemia Raynaud's phenomenon T-cell lymphoma Cytomegalovirus infection B-cell lymphoma Acute graft versus host disease in skin Astrocytoma Plasma cell myeloma recurrent Transplant rejection Epileptic encephalopathy Craniopharyngioma HER2 mutant non-small cell lung cancer Anti-HLA antibody test positive More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Treatment MELAS syndrome – Life with Disease Castleman’s disease – Treatment Antithrombin III deficiency – Basic Information Hereditary angioedema – Treatment Familial amyotrophic lateral sclerosis – Basic Information Systemic mastocytosis – Treatment Nephroblastoma – Basic Information Ornithine transcarbamoylase deficiency – Trials in Disease Idiopathic inflammatory myopathy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Istem-01 Acetylsalicylic Acid Ph. Eur. Fenoterol Hydrobromide Galcanezumab Erenumab Xanthum Gum Pemetrexed Disodium Pegargiminase ANERATRIGINE MESILATE Tovorafenib Tegoprubart Prx005 Lactulose Boserolimab Dobutamine Hydrochloride Protamine Sulfate Dapansutrile Bepirovirsen Cinchocaine Hydrochloride Guselkumab More therapies…

    Learn about Your Condition

    Breast cancer male Anal cancer recurrent Bile duct cancer Vitamin D deficiency Chronic kidney disease Neonatal hyperglycaemia Cardiac amyloidosis Immunodeficiency Oedema peripheral Agitation Palmoplantar pustulosis Hernia repair Radius fracture Pancreaticoduodenectomy Lung cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Fallopian tube cancer

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • LY4170156
    • Bevacizumab
    • Carboplatin
    Austria Belgium Czechia Denmark France Germany +9

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Fallopian tube cancer
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Cemiplimab
    • Sarilumab
    • Tocilizumab
    Belgium France Italy The Netherlands Spain

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Prednisolone Acetate
    • Mirvetuximab Soravtansine
    Belgium France Poland Spain

  • Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Peritoneal neoplasm
    • Endometrial cancer
    • Fallopian tube cancer
    Investigated Drugs:
    • Relacorilant
    • Bevacizumab
    • Paclitaxel Albumin-Bound
    Belgium France Germany Italy Poland Spain

  • Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Niraparib
    • Bevacizumab
    • Carboplatin
    Belgium Czechia Germany Italy

  • Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Endometrial cancer
    • Fallopian tube cancer
    Investigated Drugs:
    • Olaparib
    Belgium Bulgaria Czechia France Germany Hungary +6
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!